A B- és D-VÍrus hepatitis diagnosztikája, antiVIrális kezelése

Horváth Gábor, B. Hunyady, Gervain Judit, G. Lengyel, Makara Mihály, A. Pár, F. Szalay, L. Telegdy, Tornai István

Research output: Article

Abstract

Diagnosis and treatment of hepatitis B and D virus infections mean that the patient is able to maintain working capacity, increase quality of life, prevent cancer, and prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2014, which is agreed on a consensus meeting of specialists involved in the treatment of the above diseases. The prevalence of hepatitis B virus infection in the Hungarian general population is 0.5-0.7%. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline emphasizes the importance of quick and detailed virologic evaluations, the applicability of transient elastog-raphy as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection.

Original languageHungarian
Pages (from-to)25-35
Number of pages11
JournalOrvosi Hetilap
Volume155
DOIs
Publication statusPublished - 2014

Fingerprint

Chronic Hepatitis D
Chronic Hepatitis B
Therapeutics
Lamivudine
Tenofovir
Virus Diseases
Hepatitis B virus
Interferons
Hepatitis D
Guidelines
Hepatitis Delta Virus
Costs and Cost Analysis
Immunosuppressive Agents
Hepatitis B Surface Antigens
Life Expectancy
Infection
Nucleic Acids

Keywords

  • Adefovir
  • Cirrhosis
  • Entecavir
  • Hepatitis B virus
  • Hepatitis D virus
  • Interferon
  • Lamivudine
  • Liver cancer
  • Pegylated interferon
  • Tenofovir
  • Viral hepatitis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A B- és D-VÍrus hepatitis diagnosztikája, antiVIrális kezelése. / Gábor, Horváth; Hunyady, B.; Judit, Gervain; Lengyel, G.; Mihály, Makara; Pár, A.; Szalay, F.; Telegdy, L.; István, Tornai.

In: Orvosi Hetilap, Vol. 155, 2014, p. 25-35.

Research output: Article

Gábor, Horváth ; Hunyady, B. ; Judit, Gervain ; Lengyel, G. ; Mihály, Makara ; Pár, A. ; Szalay, F. ; Telegdy, L. ; István, Tornai. / A B- és D-VÍrus hepatitis diagnosztikája, antiVIrális kezelése. In: Orvosi Hetilap. 2014 ; Vol. 155. pp. 25-35.
@article{f9b3bef925e94fea972a2043bd32a7e7,
title = "A B- {\'e}s D-V{\'I}rus hepatitis diagnosztik{\'a}ja, antiVIr{\'a}lis kezel{\'e}se",
abstract = "Diagnosis and treatment of hepatitis B and D virus infections mean that the patient is able to maintain working capacity, increase quality of life, prevent cancer, and prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2014, which is agreed on a consensus meeting of specialists involved in the treatment of the above diseases. The prevalence of hepatitis B virus infection in the Hungarian general population is 0.5-0.7{\%}. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline emphasizes the importance of quick and detailed virologic evaluations, the applicability of transient elastog-raphy as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection.",
keywords = "Adefovir, Cirrhosis, Entecavir, Hepatitis B virus, Hepatitis D virus, Interferon, Lamivudine, Liver cancer, Pegylated interferon, Tenofovir, Viral hepatitis",
author = "Horv{\'a}th G{\'a}bor and B. Hunyady and Gervain Judit and G. Lengyel and Makara Mih{\'a}ly and A. P{\'a}r and F. Szalay and L. Telegdy and Tornai Istv{\'a}n",
year = "2014",
doi = "10.1556/OH.2014.29894",
language = "Hungarian",
volume = "155",
pages = "25--35",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",

}

TY - JOUR

T1 - A B- és D-VÍrus hepatitis diagnosztikája, antiVIrális kezelése

AU - Gábor, Horváth

AU - Hunyady, B.

AU - Judit, Gervain

AU - Lengyel, G.

AU - Mihály, Makara

AU - Pár, A.

AU - Szalay, F.

AU - Telegdy, L.

AU - István, Tornai

PY - 2014

Y1 - 2014

N2 - Diagnosis and treatment of hepatitis B and D virus infections mean that the patient is able to maintain working capacity, increase quality of life, prevent cancer, and prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2014, which is agreed on a consensus meeting of specialists involved in the treatment of the above diseases. The prevalence of hepatitis B virus infection in the Hungarian general population is 0.5-0.7%. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline emphasizes the importance of quick and detailed virologic evaluations, the applicability of transient elastog-raphy as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection.

AB - Diagnosis and treatment of hepatitis B and D virus infections mean that the patient is able to maintain working capacity, increase quality of life, prevent cancer, and prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2014, which is agreed on a consensus meeting of specialists involved in the treatment of the above diseases. The prevalence of hepatitis B virus infection in the Hungarian general population is 0.5-0.7%. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline emphasizes the importance of quick and detailed virologic evaluations, the applicability of transient elastog-raphy as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection.

KW - Adefovir

KW - Cirrhosis

KW - Entecavir

KW - Hepatitis B virus

KW - Hepatitis D virus

KW - Interferon

KW - Lamivudine

KW - Liver cancer

KW - Pegylated interferon

KW - Tenofovir

KW - Viral hepatitis

UR - http://www.scopus.com/inward/record.url?scp=84985986843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985986843&partnerID=8YFLogxK

U2 - 10.1556/OH.2014.29894

DO - 10.1556/OH.2014.29894

M3 - Article

AN - SCOPUS:84985986843

VL - 155

SP - 25

EP - 35

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

ER -